< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Conclusions:
The LDREBRT approach to radiotherapy dose escalation for prostate cancer appears to offer clinically meaningful benefit to patient's urinary quality of life by affording a relative decrease in urinary bother over LDRM at very high radiotherapy doses, above what is commonly prescribed. Should dose escalation be considered, the patient and care team may consider combination therapy more attractive than monotherapy because of the decrease in acute urinary morbidity.
|
|
